Alkenib 250 mg (Tablet)
Unit Price: ৳ 350.00 (1 x 30: ৳ 10,500.00)
Strip Price: ৳ 10,500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Lapatinib |
| Company | Jenphar bangladesh ltd |
Title
- Alkenib Tablets
Categories
- Breast Cancer Medication
- Chemotherapy
Description
- Tablets indicated in the treatment of advanced or metastatic breast cancer
- Kinase inhibitor of EGFR and HER2 receptors
- Absorption is incomplete and variable after oral administration
- Highly bound to albumin and alpha-1 acid glycoprotein
- Undergoes extensive metabolism by CYP3A4 and CYP3A5
- Terminal phase half-life following a single dose is 14.2 hours
- Contraindicated in patients with known severe hypersensitivity
Color Options
- White
- Off-white
Dosage & Administration
- Recommended dose of 1,250 mg given orally once daily
- Should be taken at least one hour before or after a meal
- Pediatric use not established
Interaction
- Inhibits CYP3A4, CYP2C8, and P-gp at clinically relevant concentrations
- Increased systemic exposure (AUC) when coadministered with midazolam, paclitaxel, or digoxin
- Increased exposure with concomitant administration of ketoconazole, decreased exposure with carbamazepine
Contraindications
- Severe hypersensitivity to the product or any of its components
Side Effects
- Common adverse reactions include diarrhea, palmar-plantar erythrodysesthesia, nausea, rash, vomiting, and fatigue
Pregnancy & Lactation
- Can cause fetal harm when administered to a pregnant woman
- Adverse reactions in a breastfed child
Precautions & Warnings
- Reported to decrease left ventricular ejection fraction
- Hepatotoxicity observed in clinical trials
- Severe diarrhea reported, may require oral or intravenous electrolytes and fluids
- Associated with interstitial lung disease and QT prolongation
- Severe cutaneous reactions have been reported
Use in Special Populations
- Dosage adjustment for patients with cardiac events, hepatic impairment, or diarrhea
- Avoid concomitant use with strong CYP3A4 inhibitors or inducers
Overdose Effects
- No known antidote for overdoses
- Maximum administered oral doses reported
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Store below 30°C in a dry place
- Keep out of the reach of children